NCT06925321

A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Patients With Invasive Mold Infections.

RecruitingPHASE3INTERVENTIONAL

Trial Details

Start: 2025-08-26Est. Completion: 2028-02

Enrollment target: 234 participants

Locations

University of Alabama at Birmingham School of Medicine, Department of Medicine, Birmingham, Alabama, United States
City of Hope, Duarte, California, United States
David Geffen School of Medicine at UCLA, Los Angeles, California, United States
UC Davis Medical Center, Sacramento, California, United States
Memorial Healthcare System, Hollywood, Florida, United States
Rush University Medical Center, Division of Infectious Diseases, Chicago, Illinois, United States
University of Kentucky Medical Center, Division of Infectious Diseases, Lexington, Kentucky, United States
Johns Hopkins Hospital, Baltimore, Maryland, United States
University of Michigan Health System (UMHS) - A. Alfred Taubman Health Care Center, Ann Arbor, Michigan, United States
Karmanos Cancer Institute - Detroit, Detroit, Michigan, United States
University of Minnesota, M Health Fairview Medical Center, Minneapolis, Minnesota, United States
Washington University School of Medicine, Infectious Diseases Clinical Research Unit, St Louis, Missouri, United States
Weill Cornell Medical College - NewYork-Presbyterian Hospital, New York, New York, United States

Invasive Mould Infection

The purpose of this study is to determine if EL219 is safe and effective compared to liposomal amphotericin B (LAmB) or …

Birmingham, United StatesEst. completion Dec 2026

Chronic Mucocutaneous CandidiasisInvasive AspergillosisCARD9APECED

Background: \- The immune system is made up of special cells, tissues, and organs that fight infections. Problems with …

Bethesda, United States

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.